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ReviewBalancing Acts: Molecular Control of
Mammalian Iron Metabolism
sequences of systemic iron overload result from chronic
iron accumulation in tissues.
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Cellular Iron Uptake
In normal individuals, extracellular iron circulates in theIron is ubiquitous in the environment and in biology.
plasma bound to transferrin (Tf), an abundant proteinThe study of iron biology focuses on physiology and
with extraordinarily high affinity for iron. In this form,homeostasis—understanding how cells and organ-
iron is nonreactive, but also difficult to extract. To dealisms regulate their iron content, how diverse tissues
with this, there are several Tf-dependent iron uptakeorchestrate iron allocation, and how dysregulated iron
mechanisms that mediate internalization of the entire iron-homeostasis leads to common hematological, meta-
protein complex (Figure 1). The uptake of diferric-Tf viabolic, and neurodegenerative diseases. This has pro-
transferrin receptor 1 (TfR1) has been most intensivelyvided novel insights into gene regulation and unveiled
studied (Cheng et al., 2004). Tf/TfR1 complexes localizeremarkable links to the immune system.
to clathrin-coated pits, which are endocytosed. Early Tf-
containing endosomes are acidified by a proton pump,
The Dual Challenge effecting conformational changes in both Tf and TfR1
Daily production of 200 billion new erythrocytes requires to release iron. An unidentified ferrireductase subse-
20 mg of iron for hemoglobin synthesis, accounting for quently reduces Fe3 to Fe2, allowing divalent metal
nearly 80% of the iron demand in humans. Not surpris- transporter 1 (DMT-1; also known as DCT1 or Nramp2)
ingly, significant iron deficiency leads to anemia, a major to transfer Fe2 across the endosomal membrane into
public health concern affecting up to a billion people the cytoplasm (Fleming et al., 1998). Apo-Tf and TfR1
worldwide. Eukaryotic cells (and most prokaryotic or- are recycled to the cell surface, where each can be used
ganisms) also require iron for survival and prolifera- for further cycles of iron binding and uptake. Because
tion, as a constituent of other hemoproteins, iron-sulfur TfR1 is ubiquitously expressed, Tf-mediated iron uptake
(Fe-S) proteins, and proteins that use iron in other func- is thought to occur in most cell types. However, this
tional groups to carry out essential housekeeping func- pathway appears to be most important in developing
tions for cellular metabolism. Cellular iron deficiency erythroid precursors because of their enormous need
arrests cell growth and leads to cell death. for iron for hemoglobin synthesis.
The biological importance of iron is largely attributable A homologous protein, transferrin receptor-2 (TfR2)
to its chemical properties as a transition metal. It readily (Kawabata et al., 1999), is restricted to hepatocytes,
engages in one-electron oxidation-reduction reactions duodenal crypt cells, and erythroid cells, suggesting a
between its ferric (3) and ferrous (2) states. However, more specialized role. The finding that mutations in the
the same chemical property explains why an excess of human TfR2 gene result in hemochromatosis (pathologi-
“free,” reactive iron is toxic. In the cytoplasm, a signifi- cal systemic iron overload) (Camaschella et al., 2000)
cant fraction of iron is reduced and can participate in established its importance in iron homeostasis. TfR2
“Fenton-type” redox chemistry: ferrous iron reacts with binds Tf with approximately 30-fold lower affinity than
hydrogen peroxide (H2O2) or lipid peroxides to generate TfR1 and, in contrast to TfR1, its expression is not con-
ferric iron, OH, and the highly reactive hydroxyl radical trolled by the IRE/IRP regulatory system (see below).
(OH•) or lipid radicals such as LO• and LOO•. These Polarized epithelial cells of the kidney utilize a third up-
radicals damage lipid membranes, proteins, and nucleic take mechanism for Tf bound iron, through megalin-
acids. Since both cellular iron overload and iron defi- dependent, cubilin-mediated endocytosis (Kozyraki et
ciency cause cell death, the levels of reactive iron must al., 2001). This may provide the major iron supply for
be carefully controlled and limited. Most pathologic con- renal proximal tubules.
Although Tf-dependent iron uptake probably predom-
inates under normal circumstances, pathological iron*Correspondence: hentze@embl.de
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Figure 1. Cellular Iron Metabolism
A generic mammalian cell is depicted with an
indication of iron import (top) as well as iron
export (bottom) pathways. The transferrin re-
ceptor-1 (TfR1) is ubiquitously expressed, while
transferrin receptor-2 (TfR-2) is restricted to
hepatocytes, duodenal crypt cells, and ery-
throid cells. Polarized epithelial cells of the
kidney utilize cubilin for transferrin-mediated
iron uptake. DMT-1 is implicated in intestinal
iron absorption after Fe3 from the diet is re-
duced to Fe2 by the cytochrome b-like ferri-
reductase (Dcytb). DMT-1 further functions
in iron export from the endosome following
uptake via the Tf cycle. The hemoglobin scav-
enger receptor (CD163) plays a role in hap-
toglobin-mediated hemoglobin uptake of
monocytes and macrophages. The only puta-
tive iron exporter identified to date is ferro-
portin, which has been implicated in iron
export from duodenal enterocytes, macro-
phages, hepatocytes, placenta syncytiotro-
phoblasts, and cells of the central nervous
system (CNS). Ceruloplasmin, and its intesti-
nal homolog hephaestin, oxidize Fe2 after
cellular iron export for loading onto transferrin.
Much intracellular iron traffic is directed toward
mitochondria, where the iron-dependent step
of heme synthesis and critical steps for Fe-S
cluster biogenesis are localized.
overload leads to supersaturation of transferrin iron Dietary iron uptake occurs at the apical (luminal) sur-
face of duodenal absorptive cells (enterocytes). Non-binding sites and circulating “free” iron. Several lines
of evidence indicate that there are distinct transport heme food iron exists primarily in the bio-unavailable,
insoluble Fe3 form, which must first be reduced to Fe2pathways for non-Tf bound iron. First, mice and humans
lacking Tf develop massive iron overload in nonhemato- for transport across the intestinal epithelium. The re-
sponsible enzyme appears to be a cytochrome b-likepoietic tissues, such as liver and pancreas (Trenor et
al., 2000). Second, TfR1-deficient mice show normal em- ferrireductase (Dcytb), a hemoprotein associated with
the apical enterocyte membrane (McKie et al., 2001).bryonic organ development before they succumb to se-
vere anemia in mid-gestation (Levy et al., 1999). Third, Fe2 then enters the cell through DMT-1. DMT-1 has
also been implicated in Fe2 recapture in the kidneyrapid clearance of plasma Fe is observed in diseases
(e.g., hereditary hemochromatosis) where the iron bind- (Ferguson et al., 2001; Hubert and Hentze, 2002) and in
iron transport in the brain (Jeong and David, 2003).ing capacity of Tf is exceeded.
Intestinal absorptive cells take up dietary non-Tf Iron may also be taken up by cells in other protein
bound forms such as acidic isoferritin (Meyron-Holtzbound iron directly, through the action of DMT1, the
same metal transporter that mediates iron export from et al., 1999) or hemoglobin. The latter is of particular
importance in the setting of intravascular hemolysis,the endosome following uptake via the Tf cycle (Fleming
et al., 1997; Gunshin et al., 1997). DMT-1 is a H/divalent observed in disorders such as sickle cell anemia and
thalassemia. Under these conditions, plasma hemoglo-metal symporter that also transports other divalent met-
als (e.g., Mn2, Cu2, Zn2). In addition, studies in cul- bin is captured by the acute phase protein haptoglobin
and taken up into the cell by the hemoglobin scavengertured cells indicate that there is at least one other direct
iron uptake system with properties distinct from DMT1 receptor (CD163), which is expressed on monocytes and
macrophages (Kristiansen et al., 2001).(Sturrock et al., 1990). Calcium channels may, under
some circumstances, mediate the uptake of iron (Oudit Thus, different means of cellular iron uptake have
evolved to accommodate different forms of iron and,et al., 2003; Mwanjewe and Grover, 2004). In addition,
iron can be complexed by neutrophil gelatinase-associ- probably, to allow differential regulation. Biochemical
data suggest that additional iron uptake mechanismsated lipocalin (NGAL/24p3) in a form that is internalized
and trafficked to late endosomes with acidic pH (Yang may exist (e.g., through putative receptors for ferritin
and hemopexin), but these have not yet been character-et al., 2002a). Recombinant NGAL/24p3 loaded with iron
has been shown to deliver the metal into cultured cells, ized at a molecular level or in vivo.
Finally, substantial iron uptake by tissue macrophagesaffecting the expression of iron-responsive genes. This
NGAL/24p3 delivery pathway appears to be important in occurs through an indirect route. Old and damaged red
blood cells are phagocytosed by a specialized macro-differentiating epithelial cells during early development
(Yang et al., 2002a). phage population that serves the purpose of recycling iron
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from hemoglobin for re-use (Brittenham, 1994). Engulfed import into tissue culture cells (e.g., Mukhopadhyay et
al., 1998), but this has not yet been confirmed.red cells are lysed, hemoglobin is degraded (with help
from heme oxygenase), part of the recovered iron is Regulation of Cellular Iron Homeostasis
Proteins involved in iron uptake, storage, utilization, andheld in storage, and the remainder is exported to reload
circulating Tf. This is quantitatively important; only 1–2 export must be regulated in a coordinated fashion. The
signals and regulatory mechanisms that orchestratemg of iron enters the body through the intestine each
day, yet 25 mg are needed for erythropoiesis and other their expression involve modulation of transcription,
mRNA stability, translation, and posttranslational modi-uses. Nearly all of the available iron pool is derived from
macrophage recycling (Figure 3). fications. Posttranscriptional regulation is best charac-
terized (Figure 2). Trans-acting iron regulatory proteinsCellular Iron Storage
Once iron enters the cell, the portion that is not needed (IRPs) interact with iron-responsive elements (IREs),
which are conserved hairpin structures found in untrans-for immediate use is stored by ferritin, a ubiquitous and
highly conserved multimeric protein (Figure 1) (Torti and lated portions of mRNAs encoding iron-related proteins.
Single IREs are located in the 5 untranslated regionsTorti, 2002). In vertebrates, ferritin consists of an apo-
protein shell of 24 light (L) and heavy (H) chain subunits, (UTRs) of mRNAs encoding ferritin H and L chains, ery-
throid 5-aminolevulinic acid synthase (the first enzymesurrounding a core of up to 4500 iron atoms. Ferritin
sequesters the metal from the intracellular labile iron of heme biosynthesis), mitochondrial aconitase (a citrate
cycle enzyme), and ferroportin (Hentze and Ku¨hn, 1996;pool, locking it up in chemically less reactive ferrihydrite
to achieve both iron storage and detoxification (Harrison, Donovan et al., 2000; McKie et al., 2000; Eisenstein and
Ross, 2003). The formation of IRE/IRP complexes on1977). The ratio of H to L subunits varies depending on
tissue type and physiologic status and changes in re- the 5 UTR serves to inhibit early steps of the translation
process (Muckenthaler et al., 1998). Proximity of thesponse to inflammation or infection. Ferritin has enzy-
matic properties, converting Fe2 to Fe3 as iron is IRE to the transcription start site is important for this
mechanism of translational control, and alteration of theinternalized and packed into the mineral core. This fer-
roxidase activity is an inherent feature of the H subunit. transcription start site can impart differential responses
to IRP binding (Paraskeva et al., 1999).Degradation of ferritin and concomitant iron release
helps to mobilize iron for cellular utilization. Little is A second type of regulation occurs when IREs are
located beyond the coding sequence. Multiple IREs inknown about how ferritin is degraded, but both lyso-
somal and proteosomal pathways have been implicated. the 3 UTR of TfR1 mRNA serve to stabilize the mRNA
upon IRP binding (Hentze and Ku¨hn, 1996). A single IREA unique H-type ferritin homopolymer is expressed in
mitochondria (mitochondrial ferritin [MtF]) (Levi et al., was identified in the 3 UTR of one isoform of DMT-1.
However, this IRE only marginally mediates iron regula-2001). Experimental overexpression of MtF results in
mitochondrial iron accumulation, decreased cytosolic tion in cultured cells (Gunshin et al., 2001), and its mech-
anism of action is not well understood. The situation isferritin, and increased TfR1 expression. Interestingly,
MtF expression is increased in anemia disorders charac- more complex, as a 5 promoter/exon 1A region acts
with the 3 IRE-containing terminal exon to controlterized by mitochondrial iron accumulation (sideroblas-
tic anemias), suggesting a protective role of MtF against DMT-1 expression (Hubert and Hentze, 2002).
Diverse IREs display remarkable structural similarity.iron-mediated toxicity.
Cellular Iron Export Canonical IREs have a six nucleotide apical loop with
the consensus sequence 5-CAGUGN-3 on a stem ofDuodenal enterocytes, macrophages, hepatocytes, pla-
centa syncytiotrophoblasts, and cells of the central ner- five paired bases, a small asymmetrical bulge with an
unpaired cytosine on the 5 strand, and an additionalvous system (CNS) require mechanisms to release iron
in a controlled fashion to ensure availability of the metal stem of variable length (Hentze et al., 1988). The nucleo-
tides making up the two stem segments may vary con-where it is needed. The only putative iron exporter identi-
fied to date is ferroportin (also known as Ireg1, MTP) siderably.
The cellular labile iron pool regulates binding of IRP1(Abboud and Haile, 2000; Donovan et al., 2000; McKie et
al., 2000). It is highly expressed in iron-deficient intestine and IRP2 to IREs through distinct mechanisms. When
iron levels are high, a cubane [4Fe-4S] cluster assemblesand in tissue macrophages. Ferroportin is located at the
basolateral membrane of duodenal enterocytes, where in IRP1, inhibiting IRE binding activity and converting
IRP1 to an aconitase. When cellular iron stores are low,it mediates iron export into the bloodstream, apparently
in concert with hephaestin, a ferroxidase that is homolo- IRP1 binds to IRE targets as an apoprotein. In contrast,
IRP2 does not contain an Fe-S cluster. It accumulatesgous to the abundant plasma protein ceruloplasmin (Vulpe
et al., 1999). in iron-deficient cells and is targeted for degradation
when iron levels are high (Hentze and Ku¨hn, 1996). Sur-Iron export from nonintestinal cells requires cerulo-
plasmin (Cp) (Harris et al., 1999). Cp converts Fe2, likely prisingly, it was recently reported that mice on an iron-
deficient diet activated IRP2 but failed to increase IRP1exported by ferroportin, to Fe3 that is loaded onto Tf
for transport in the plasma (Figure 1). In the brain, the activity (Meyron-Holtz et al., 2004). This contrasts with
findings from cultured cells and suggests that IRP1 ac-glycosylphosphatidylinositol (GPI)-anchored form of Cp
physically interacts with ferroportin to export iron from tivity may not be determined by a simple iron equilib-
rium reaction.astrocytes (Jeong and David, 2003). Patients and mice
with Cp deficiency accumulate iron in macrophages, IRP1 and IRP2 share extensive sequence homology,
but IRP2 contains a 73 amino acid N-terminal insertionhepatocytes, and cells of the CNS, resulting in iron-
restricted erythropoiesis and neurodegeneration. Some that has been implicated in iron-sensing and iron-medi-
ated degradation. It can bind heme, triggering oxy-reports suggest that Cp may also be involved in iron
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Figure 2. The IRE/IRP Regulatory System
Proteins involved in iron storage, erythroid
heme synthesis, the TCA cycle, iron export,
and iron uptake are coordinately regulated by
the interaction of the iron regulatory proteins
(IRPs) with conserved RNA secondary struc-
tures, the iron-responsive elements (IREs).
The binding of IRPs to single IREs in the
5-untranslated regions (UTRs) of mRNAs
blocks their translation, while IRP binding to
multiple IREs in the 3 UTR stabilizes the
TfR-1 mRNA. IRPs exist in two isoforms, IRP1
and IRP2. Increased iron levels favor the con-
version of IRP1 from its active RNA binding
form into an Fe-S cluster containing cyto-
plasmic aconitase that lacks IRE binding ac-
tivity as well as the proteasomal degradation
of IRP2. Low iron levels or the action of NO
promote accumulation of the active apopro-
tein form of IRP1 and stabilize IRP2. In con-
trast, H2O2 only activates IRP1, while hypoxia
interferes with IRP2 degradation.
gen-dependent oxidation, ubiquitination by the E3 ubi- kin-1, interleukin-6, and interferon- (IFN-) all stimulate
H-ferritin expression but reduce TfR1 expression (Tortiquitin-protein ligase HOIL1, and degradation by the
proteasome (Kang et al., 2003; Yamanaka et al., 2003). and Torti, 2002). IFN- and lipopolysaccharide have
been reported to induce DMT-1 and inhibit ferroportinHowever, other reports suggest that this domain is dis-
pensable for iron-mediated IRP2 degradation and that expression in activated monocytes (Ludwiczek et al.,
2003; Yang et al., 2002b). The ferroportin response to2-oxoglutarate-dependent oxygenases are involved in
regulation (Bourdon et al., 2003; Hanson et al., 2003; lipopolysaccharide appears to be mediated by Toll-like
receptor 4 and, in part, by IRP-dependent regulation ofWang et al., 2004). Thus, the mechanisms of IRP1 and
IRP2 regulation are less clear than they had appeared the IRE-containing ferroportin mRNA (Liu et al., 2002).
Together, these cytokine-induced changes may contrib-to be.
IRPs are also controlled by other effectors including ute to macrophage iron retention observed in inflamma-
tory states, augmenting the host defense against micro-reactive oxygen species, which lead to disassembly of
the Fe-S cluster of IRP1 (Pantopoulos and Hentze, 1998), organisms.
Intracellular Iron Distributionand nitric oxide and hypoxia, which affect both IRPs
(Hentze and Ku¨hn, 1996; Hanson et al., 1999). Serine Most of the iron within cells is routed to the mitochon-
dria, where substantial amounts are needed for hemephosphorylation of IRP1 destabilizes the Fe-S cluster,
suggesting an additional, iron-independent mechanism biosynthesis and maturation of Fe-S clusters (Figure 1).
In erythroid cells, where nearly all iron is needed forof IRP1 regulation (Brown et al., 1998; Fillebeen et al.,
2003). heme synthesis, iron-loaded endosomes have been pro-
posed to make direct contact with mitochondria to facili-It is clear that other translational control mechanisms
will turn out to be important in regulating iron homeosta- tate accumulation of large amounts of iron (Ponka,
1997). This model is intriguing, but not yet proven.sis. Exploiting an IRP-independent mechanism, IFN-
silences translation of ceruloplasmin mRNA, apparently Mitochondrial iron also accumulates in yeast (Gerber
and Lill, 2002) and humans (Allikmets et al., 1999) withthrough the interaction of a phosphorylated ribosomal
protein with a novel element located in the 3 UTR (Ma- defects in proteins involved in Fe-S cluster assembly.
Human ABC7 and its functional yeast ortholog Atm1pzumder et al., 2003). It is not yet known whether this
mechanism is used for regulation of other mRNAs. are thought to function in the export of Fe-S clusters
from mitochondria. Mutations in ABC7 result in anemiaIron-related genes are also regulated at the level of
transcription. Cytokine responses have been reported and neurological symptoms. Erythroid precursor cells
from affected patients contain mitochondrial iron aggre-for many. For example, tumor necrosis factor-, interleu-
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gates. ABC7 may play a role in heme biosynthesis, poiesis, intestinal absorption is enhanced by an “ery-
throid regulator” (Finch, 1994). Iron homeostasis is alsothrough a direct interaction with ferrochelatase, the final
altered in response to hypoxia, through a humoral “hyp-enzyme in the pathway (Taketani et al., 2003).
oxia regulator.”Defects in the frataxin gene cause the neurodegenera-
The hierarchy of regulators is discernible in situationstive disorder Friedreich ataxia. Friedreich ataxia patients
where erythropoiesis is iron deficient, yet tissue ironand mice with muscle- or neuron-specific frataxin gene
stores are overfilled. Hypotransferrinemic (Trf hpx ) miceinactivation display progressive deficiency of Fe-S clus-
with a splice donor mutation that results in near totalter containing proteins followed by mitochondrial iron
deficiency of serum Tf are one example (Trenor et al.,overload (Rotig et al., 1997). Frataxin is a mitochondrial
2000). Receptor-mediated endocytosis of Tf is essentialmatrix protein that has postulated roles in mitochondrial
for iron uptake by erythroid precursors (Levy et al., 1999)iron export (Chen et al., 2002) and iron storage (Adamec
and erythropoiesis is severely impaired in Trf hpx miceet al., 2000). Recent work in yeast demonstrated that
because the supply of iron bound to Tf is inadequate.frataxin is required for de novo biogenesis of cellular
However, as discussed earlier, nonhematopoietic tis-Fe-S proteins (Muhlenhoff et al., 2003). It binds to the
sues avidly assimilate non-Tf bound iron, and the liver,central Fe-S cluster-assembly complex in an iron-
pancreas, and other organs develop iron overload. Independent manner where it may support iron loading of
this setting, the erythroid regulator overrides the storesthe complex (Gerber et al., 2003). Interestingly, frataxin
regulator, resulting in vigorous intestinal absorption ofexpression is reduced during erythroid differentiation,
dietary iron and consequent deposition of excess iron inand it is tempting to speculate that this may serve to
parenchymal cells. Plasma transferred from Trf hpx micedivert mitochondrial iron toward heme biosynthesis.
failed to increase iron absorption in recipients (BuysWe still understand little about how iron enters mito-
et al., 1991), suggesting that, if the erythroid regulatorchondria or how trafficking to mitochondria is regulated.
involves a soluble factor, the factor is short-lived, or theRecently, it was proposed that an Fe-S protein might
signal results from a decrease, rather than increase, inact as a sensor of the mitochondrial iron status. If this
its production. A possible caveat to this interpretationputative sensor lacks its Fe-S cluster, mitochondrial iron
is the fact that Tf levels are unusually low. However, awould accumulate through increased mitochondrial iron
similar predominance of the erythroid regulator is appar-uptake and/or decreased iron release. Iron sequestra-
ent in patients with thalassemia syndromes. They havetion would continue until requirements for Fe-S cluster
increased erythropoietic drive due to destruction of im-assembly were satisfied. Thereafter, the amount of iron
mature erythroid cells in the bone marrow, leading toremaining in a postmitochondrial, cytoplasmic iron pool
increased intestinal iron absorption even after other tis-would be sensed, in some fashion, to regulate cellular
sues become iron overloaded.iron absorption (Pandolfo, 2002). However, mutations
Cellular iron retention occurs rapidly in the settingsin aminolevulinate synthase, the first enzyme in heme
of infection and inflammation, presumably to withholdsynthesis, also cause mitochondrial iron accumulation.
a nutrient from invading pathogens. Iron accumulatesThis suggests a more complicated process for regulat-
in macrophages that recycle the metal from senescenting mitochondrial iron influx.
erythrocytes, and intestinal iron absorption is interrupted.
This can be considered an “inflammatory regulator.”
Systemic Iron Homeostasis
These different regulators (erythroid, stores, hypoxia, and
Systemic Regulators inflammatory) need not be completely independent.
Systemic iron homeostasis, the control of iron balance Rather, they might represent quantitative differences in
throughout the body, requires mechanisms for regulat- responses mediated by the same molecule(s).
ing iron entry into and mobilization from stores, for meet- Serum plasma iron levels are determined both by in-
ing erythropoietic needs, and for scavenging previously testinal absorption and macrophage recycling of iron
used iron. There is no efficient pathway for iron excre- from hemoglobin (Figure 3). Regulatory effectors that
tion; hence, intestinal absorption must be modulated to modulate intestinal iron absorption probably also modu-
provide enough (but not too much) iron to keep stores late release of iron from tissue macrophages and hepa-
replete and erythroid demands met. There must be ef- tocytes. The search for these molecules has focused
fective communication between cells that consume iron on plasma proteins that might act at multiple sites. Some
(primarily erythroid precursors) and cells that acquire plausible candidates, e.g., erythropoietin, have likely
and store iron (duodenal enterocytes, hepatocytes, tis- been ruled out (Raja et al., 1986).
sue macrophages). Transfer between tissues must be Hepcidin (HAMP, LEAP) appears to be such a regula-
orchestrated to maintain homeostasis (Figure 3). tory effector. It is a small, cysteine-rich peptide, cleaved
In normal adults, storage iron is deposited in hepato- from a larger precursor (Krause et al., 2000; Park et al.,
cytes and tissue macrophages and mobilized in re- 2001; Pigeon et al., 2001). Hepcidin is secreted by the
sponse to acute need. Intestinal iron absorption is regu- liver and excreted through the kidneys (Krause et al.,
lated, in part, in response to a signal that communicates 2000; Park et al., 2001). It resembles peptides involved
information about the amount of iron in the depot—the in innate immunity and has antimicrobial properties
“stores regulator” (Finch, 1994). Erythroid cells are the (Krause et al., 2000; Park et al., 2001). Mice that fail
major consumers of iron, and the iron endowment of to express hepcidin have elevated body iron stores,
the erythron (bone marrow, erythroid precursors plus presumably due to hyperabsorption, associated with
circulating red blood cells) normally exceeds the amount decreased iron in tissue macrophages (Nicolas et al.,
present in stores. When erythroid demand surpasses 2001, 2002a). Hepcidin expression increases when ex-
cess iron is administered (Pigeon et al., 2001; Mucken-the capacity of storage cells to mobilize iron for erythro-
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Figure 3. Systemic Iron Homeostasis
Major pathways of iron traffic between cells
and tissues are depicted. Normal (human)
values for the iron content of different organs
and tissues are stated, and the approximate
daily fluxes of iron are also indicated. Note
that these values are approximate and sub-
ject to significant person-to-person variation.
Iron losses result from sloughing of skin and
mucosal cells as well as blood loss. Impor-
tantly, there exists no regulated excretion path-
way to control systemic iron homeostasis.
thaler et al., 2003), suggesting a compensatory response transcription. Analysis of the putative promoter revealed
to limit intestinal absorption. Transgenic mice constitu- binding sites for CCAAT/enhancer binding protein
tively expressing hepcidin have profound iron deficiency (C/EBP) and hepatocyte nuclear factor 4 (HNF4)
(Nicolas et al., 2002a). These observations make hep- within an 800 bp segment that conferred liver-specific
cidin an attractive candidate for a soluble regulator that expression (Courselaud et al., 2002). In reporter assays,
acts to attenuate both intestinal iron absorption and C/EBP activated transcription and HNF4 repressed
macrophage iron release (Figure 4). it. Furthermore, compared to wild-type animals, C/EBP
Increased hepcidin expression in iron-loaded animals knockout mice expressed less hepcidin and developed
and hypertransfused human patients suggests that it is mild iron overload, while HNF4 knockout mice ex-
a component of the stores regulator. However, anemic, pressed more hepcidin (Courselaud et al., 2002). Al-
iron-loaded Trf hpx mice express very little hepcidin though wide ranges in mRNA expression have been
(Weinstein et al., 2002), suggesting that it is also a com- observed, production may also be regulated at the level
ponent of the erythroid regulator. Hepcidin expression of pre-protein cleavage and/or secretion. Owing to its
decreases in response to non-anemic hypoxia, implicat- small size, hepcidin is probably cleared quantitatively
ing the peptide in the hypoxia regulator (Nicolas et al., by the kidneys, allowing for rapid alteration of circulat-
2002b). Increased hepcidin expression observed in mice ing levels.
and human patients with inflammation suggests that it Genetic experiments have suggested that hepcidin
contributes to the inflammatory regulator (Weinstein et attenuates iron release from enterocytes, placental syn-
al., 2002; Nemeth et al., 2003; Nicolas et al., 2002b). cytiotrophoblasts, and macrophages. It was recently re-
Although correlative changes in expression appear to ported that injection of synthetic hepcidin peptide into
link hepcidin to these regulators, the signaling pathways mice inhibited iron uptake in isolated duodenal seg-
have not been worked out. Interleukin-6 induces hep- ments (Laftah et al., 2004). Unfortunately, the hepcidin
cidin mRNA expression in vitro (Nemeth et al., 2003) and
peptide mixture was heterogenous, and the amount of
in vivo (Nemeth et al., 2004), linking hepcidin production
native, active hepcidin was not determined. In contrast
to the inflammatory regulator. However, neither ferric
to the conclusions of other investigators, these authorsiron nor iron-loaded Tf induced hepcidin expression in
suggested that hepcidin predominantly acted to dimin-cultured hepatic cells; in fact, ferric iron treatment led
ish iron transport across the apical membrane, with littleto decreased hepcidin production. No molecular link
or no effect on basolateral iron transfer. However, thehas yet been found between hepcidin expression and
effects were small, and a time lag between hepcidinthe erythroid and hypoxia regulators.
injection and effect on absorption makes the experi-Is hepcidin the sole downstream effector for all four
ments difficult to interpret. It will be important to resolveregulators described above? Although hepcidin produc-
this issue in future studies.tion is attenuated when erythropoiesis is iron restricted,
No hepcidin receptor has been identified to date, butactivation of the erythroid regulator in Trf hpx mice also
it is assumed that hepcidin interacts with a cell surfaceleads to markedly increased expression of Dmt1, ferro-
protein. Hepcidin binding might signal the inactivationportin, and Dcytb mRNAs (McKie et al., 2000, 2001;
of the cellular iron export apparatus through decreasedCanonne-Hergaux et al., 2001). The increased expres-
expression or modification of its components. Alterna-sion of these transport-related proteins may result from
tively, hepcidin might bind directly to ferroportin or anan additional signal acting to augment iron absorption,
associated transport molecule. Characterization of thebeyond decreased hepcidin production.
mechanism of hepcidin action is a priority for iron biolo-Hepcidin mRNA is highly expressed in normal liver,
and much regulation appears to occur at the level of gists.
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Figure 4. Role of Hepcidin, HFE, and Other
Molecules in the Regulation of Systemic
Iron Homeostasis
Hepcidin is an antimicrobial,  defensin-like
peptide secreted by the liver. It diminishes
iron release from reticuloendothelial macro-
phages and duodenal enterocytes. As a con-
sequence, serum iron levels decrease. Hep-
cidin expression is regulated by iron levels,
inflammatory stimuli, the erythroid iron de-
mand, and hypoxia. Recent data indicate
that the former two responses require HFE
function.
IRE/IRP in Systemic Iron Homeostasis Autosomal dominant hyperferritinemia-cataract syn-
drome is caused by loss-of-function mutations in theThe IRE/IRP regulatory system may also be important
in controlling systemic iron balance. IREs are found in IRE of ferritin L chain mRNA (Cazzola and Skoda, 2000).
Multiple, independent mutations have been describedmRNAs encoding two critical duodenal iron transport-
ers, ferroportin and DMT1, strongly suggesting that IRPs that impair IRP binding, causing de-repression of ferritin
L chain translation. Remarkably, the loss of this house-are involved in their posttranscriptional regulation. Di-
rect experimental evidence for a functional role of the keeping function does not cause severe disturbances of
systemic iron metabolism. Bilateral, early-onset cataractsIRE in the 3-untranslated region of DMT1 mRNA is lim-
ited, but the IRE in the 5 UTR of ferroportin mRNA has and increased serum ferritin levels are the only clini-
cal features.been shown to mediate iron-dependent translational
control in cell lines (Abboud and Haile, 2000). Iron Overload Disorders
A heterogeneous group of inherited iron overload condi-Surprisingly, the phenotype of IRP1/ mice is rather
mild, suggesting that IRP2 can fully compensate for the tions result from increased intestinal absorption and
deposition of iron in vital organs. Mutations in four geneslack of IRP1 under normal circumstances (Meyron-Holtz
et al., 2004). However, IRP2/ animals misregulate iron (HFE, TFR2, hemojuvelin, and hepcidin) have been found
in patients with “hemochromatosis,” and mutations inmetabolism in the duodenal mucosa, resulting in in-
creased expression of DMT1, ferritin, and ferroportin ferroportin have been identified in a pathologically dis-
tinct disorder.and increased duodenal iron content (LaVaute et al.,
2001). IRP2-deficient mice are also reported to have The prototype, HLA-linked hemochromatosis, is char-
acterized by iron accumulation in the liver, heart, andelevated serum ferritin and increased liver iron. As dis-
cussed later, they develop a neurodegenerative pheno- pancreas, with relative sparing of macrophages. Com-
plications, resulting from destructive changes, includetype. Tissue-specific ablation of IRP2 will be necessary
to elucidate how loss of this protein leads to these pro- liver cirrhosis, heart failure, and diabetes. When identi-
fied before severe damage ensues, hemochromatosistean manifestations.
Interestingly, a single point mutation in the IRE of can be treated by phlebotomy (blood-letting) to remove
iron-rich red blood cells. Although now deleterious, theferritin H chain mRNA (A49U) is associated with autoso-
mal dominant iron overload affecting three members of hemochromatosis mutation may have been subject to
positive selection at times when the diet provided littlea Japanese family (Kato et al., 2001). The A49U IRE
mutation appears to increase IRP binding, resulting in bioavailable iron. Only a fraction of patients with a
hemochromatosis genotype develop iron overload, anddecreased H chain ferritin expression. Ferritin L chain
levels are increased, possibly due to titration of the IRP environmental factors affect disease penetrance. In ad-
dition, genetic factors likely determine individual sus-repressors by the higher affinity mutant IRE. These ob-
servations suggest that regulation of ferritin (H chain) ceptibility to iron loading.
HFE encodes an atypical major histocompatibilityexpression by the IRE/IRP system is important for the
maintenance of systemic iron homeostasis. It will be class I protein that heterodimerizes with-2 microglobu-
lin but does not bind a small peptide (Feder et al., 1996;important to firmly establish the IRE mutation as the
genetic cause of the iron overload and to investigate Lebron et al., 1998). Most affected patients are homozy-
gous for a missense mutation (C282Y) (Feder et al., 1996)the underlying mechanism(s).
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that partially disrupts HFE function. A very common mis- Non-HFE Hemochromatosis
Some patients with severe, early onset (juvenile) hemo-sense mutation, H63D, apparently confers a slight pre-
chromatosis are homozygous for mutations in HAMP,disposition to iron loading (Tomatsu et al., 2003) but is
the human gene encoding hepcidin (Roetto et al., 2003).rarely clinically significant unless found in patients who
Furthermore, patients with HFE mutations in combina-also carry a C282Y mutation on their other HFE allele.
tion with heterozygous HAMP mutations have a moreOther HFE mutations have been described, but most
severe phenotype than relatives who only carry HFEare rare and their association with clinical disease is not
mutations. These observations lend additional supportalways certain.
to the idea of an HFE/hepcidin axis.The normal function of HFE is unknown. Importantly,
Some non-HFE hemochromatosis patients carry non-it forms a high-affinity complex with TfR1 (Parkkila et
sense and missense mutations in the gene encodingal., 1997; Lebron et al., 1998). Co-crystallization revealed
TfR2 (Camaschella et al., 2000), which does not forman extensive interaction interface between the two mole-
a complex with HFE. TfR1/TfR2 heterodimers can becules (Bennett et al., 2000), which overlaps the Tf binding
detected when the two proteins are coexpressed, butsite on TfR1. In vitro, HFE competitively inhibits Tf bind-
it is not clear that they form in vivo. It is not yet knowning. At high concentrations of HFE, two HFE molecules
how TfR2 relates to HFE and hepcidin.bind to the TfR homodimer (Bennett et al., 2000). At
Other patients with autosomal recessive, juvenilelower concentrations, a complex can be formed that
hemochromatosis carry mutations in a novel gene, hem-includes HFE, TfR1, and Tf in a 1:2:1 stoichiometry (Le-
ojuvelin (HFE2) (Papanikolaou et al., 2004). While it wasbron et al., 1998). It remains unclear what the stoichiom-
expected that this second juvenile hemochromatosis
etry is in vivo. Fe2-Tf binds to TfR1 with higher affinity gene might encode a receptor for hepcidin, it is not
and is present in plasma at micromolar concentrations. obvious that hemojuvelin serves that function. First, it
However, HFE is tethered to the same membrane sur- is expressed predominantly in skeletal muscle, heart,
face as TfR, favoring a bimolecular interaction. and liver. Second, patients with hemojuvelin mutations
Tf-mediated iron uptake was decreased in transfected have decreased urinary hepcidin levels. The only de-
HeLa cells expressing HFE (Gross et al., 1998), consis- scribed homolog of hemojuvelin is a chicken axonal pat-
tent with the finding that HFE binding precludes binding terning molecule (repulsive guidance molecule, RGM),
of Fe2-Tf. However, others reported that coexpression which has no known connection to iron metabolism. At
of HFE and 2-microglobulin increases iron uptake in present, it is not known whether hemojuvelin is another
transfected CHO cells, by enhancing recycling of TfR1 component of the hepcidin regulatory pathway or a key
to the cell surface following endosomal iron release molecule in a parallel regulatory pathway.
(Waheed et al., 2002). Regardless of the interpretation A distinct iron overload disease with autosomal domi-
of these conflicting studies, it is important to consider nant inheritance results from heterozygosity for muta-
that studies of HFE/TfR1 interactions in transfected cells tions in the gene encoding ferroportin (Montosi et al.,
may be misleading; the cellular context is inappropriate 2001; Njajou et al., 2001). Affected individuals have iron
and the stoichiometry is influenced by the fact that HFE accumulation in macrophages, but relatively normal se-
rum iron levels. Because there is no robust assay foris overexpressed.
ferroportin activity, it is not yet certain how these muta-It is assumed that HFE does not directly modify dietary
tions affect protein function. The pattern of iron loadingiron uptake because the Tf cycle is not operative at the
suggests a defect in the recycling of iron already withinapical surface of absorptive enterocytes. Until recently,
the body, rather than a primary increase in intestinalit was widely believed that HFE acts in intestinal crypt
absorption. Ferroportin is highly expressed by the retic-cells, helping to program their future absorptive capacity
uloendothelial macrophages that unload iron from he-as they differentiate into mature enterocytes. However,
moglobin scavenged from senescent red blood cells.emerging information about hepcidin suggests that the
The flux of iron through these macrophages is muchcrypt cell may not be the critical site of HFE function.
greater than the flux through intestinal epithelial cellsIn contrast to mice with induced iron overload, hepcidin
(Figure 3), suggesting that loss of one ferroportin alleleexpression was not increased in Hfe/ mice (Ahmad et
makes recycling less efficient, leading to a misinterpre-al., 2002; Muckenthaler et al., 2003; Nicolas et al., 2003)
tation of body iron stores (Montosi et al., 2001). Conse-
or in patients with HFE hemochromatosis (Bridle et al.,
quently, there may be a signal to increase intestinal
2003). Strikingly, the unique difference in hepatic gene absorption to meet iron demands. While this model is
expression between Hfe/ mice and wild-type mice attractive, it has not yet been proven.
injected with iron dextran was that hepcidin expression Animal Models
was not increased in the former (Muckenthaler et al., Historically, animal models have taken advantage of
2003). Constitutive expression of hepcidin on an Hfe/ strong parallels between human and rodent iron metab-
background prevented iron overload (Nicolas et al., olism. Recent studies of iron transport have been ex-
2003). Hfe/ mice fail to induce hepcidin appropriately tended to other species. In addition, targeted mutagene-
in response to inflammatory stimuli (Roy et al., 2004). sis has generated new classes of mutant mice (Table
Together, these observations suggest that (1) HFE and 1), which serve three general purposes: development of
hepcidin are parts of the same regulatory axis and (2) mouse models of human diseases (e.g., hemochro-
HFE might function “upstream” of hepcidin expression matosis, aceruloplasminemia, Friedreich’s ataxia), inter-
(Figure 4). New models for HFE function must take these rogation of the roles of iron-related proteins in vivo (e.g.,
TfR1, H-ferritin, IRPs), and discovery of previously un-facts into account.
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Table 1. Animal Models Useful for Understanding Iron Biology and Related Diseases
Type of Analogous
Strain Gene (Mutation) Mutation Iron Phenotype Human Disease
Hfe/ and HfeC282Y/C282Y
a
Hfe TMM Hepatocellular iron deposition, decreased HFE HC
macrophage iron, elevated transferrin
saturation
2m/ Beta-2 microglobulin TMM Parenchymal iron deposition ND
Usf2/ Hepcidinb TMM Hepatocellular iron deposition, decreased Juvenile HC
macrophage iron, elevated transferrin
saturation
Hamp—liver spec. transgene Hepcidin TgM Iron deficiency and anemia NA
Hfe/ and Hamp transgene Hepcidin/HFE CMM Amelioration of hepatic iron loading NA
relative to Hfe/ mice
TfR/ Transferrin receptor-1c TMM Microcytic hypochromic erythrocytesf, ND
decreased iron stores
TfRr2245x/245x Transferrin receptor-2 TMM Hepatocellular iron deposition, decreased TfR2 HC
macrophage iron, elevated transferrin-
saturation
hpx Transferrin SMM Microcytic hypochromic anemia, tissue Atransferrinemia
iron deposition
mk DMT1 (G185R) SMM Systemic iron deficiency; impaired iron ND
uptake in the duodenum and in erythroid
precursors
b (Belgrade rat) DMT1 (G185R) SRM Systemic iron deficiency; impaired iron ND
uptake in duodenum and in erythroid
precursors
cdy (Chardonnay) DMT1 (missense, IZM Hypochromic anemia ND
nonsense)
weh (Weissherbst) Ferroportin IZM Hypochromic anemia, impaired iron ND
transfer from yolk sac to embryo
Cp/ Ceruloplasmin TMM Iron accumulation in hepatocytes and Aceruloplasminemia
macrophages
sla Hephaestin (deletion) SMM Microcytic hypochromic anemia, impaired ND
intestinal iron transfer
Fth/ H-Ferritind TMM Elevated tissue and serum L-ferritin ND
Ireb2/ IRE binding protein 2 TMM Iron deposition in enterocytes, neurons ND
and oligodendrocytes
f (flexed tail) Sideroflexin 1 SMM Transient fetal and neonatal anemia with ND
(frameshift) intracellular iron deposits
Frda - tissue specific k.o. Frataxin TMM Mitochondrial iron deposits, neurodegen- Friedreich ataxia
neuron/hearte eration and cardiomyopathy
Frda - tissue specific k.o. Frataxin TMM Mitochondrial iron deposits; Friedreich ataxia
musclee cardiomyopathy
Hmox1/ Heme oxygenase 1 TMM Anemia, low serum iron levels, tissue iron Hmox 1 deficiency
deposition
ND: not described; SMM: spontaneous mouse mutant; TMM: targeted mouse mutant; NA: not applicable; SRM: spontaneous rat mutant; TgM:
transgenic mouse;
HC: hemochromatosis; IZM: induced zebrafish mutant; CMM: compound mutant mouse
a Mutation is in mouse codon 294.
b Includes deletion of gene for upstream stimulatory factor-2.
c Trfr/ mice: embryonic lethal by E 12.5.
d Fth/ mice: early embryonic lethality.
e Frda/ mice: early embryonic lethality; beta-cell ko: loss of beta cells, diabetes mellitus.
f Reduction in red cell size and hemoglobin content.
suspected links between proteins with other functions There is substantial variation in baseline iron parame-
ters among inbred mouse strains. In the coming years,and the regulation of iron balance (e.g., hepcidin).
Breeding and analysis of compound mutants extend quantitative trait locus analysis in mice is likely to yield
information on genes that modify the hemochromatosisthe power of these genetic studies. Compound mutants
have confirmed that iron loading in HFE hemochro- phenotype and/or predispose to iron deficiency in hu-
man patients.matosis results from enhanced flux of iron through
known transport pathways, rather than through activa- The Iron-Immune System Connection
There are remarkable interconnections between irontion of an accessory absorptive pathway (Levy et al.,
2000). As in human patients, HFE hemochromatosis pro- metabolism and the immune system (De Sousa et al.,
1988). DMT1, the major iron uptake molecule, is a closemotes a porphyric phenotype in mice heterozygous for
mutations in the uroporphyrinogen decarboxylase gene homolog of Nramp1, a metal transporter localized to
phagolysosomes, which mediates macrophage resis-(Phillips et al., 2001).
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tance against intracellular pathogens. Tf and TfR1 play oxidative stress without frank neurodegeneration (Thomp-
son et al., 2003).essential roles in lymphocyte development and activa-
tion. 2-microglobulin, the heterodimeric partner of Dramatic, localized, iron accumulation is observed in
Hallervorden-Spatz neurodegenerative disease, whichHFE, is a key component of the immune surveillance
mechanism. Lactoferrin and transferrin bind iron to se- is due to mutations in a pantothenate kinase (PANK)
gene. PANK is essential for the synthesis of coenzymequester it from invading pathogens. Hepcidin has intrin-
sic antimicrobial activity of uncertain importance. Heme A from pantothenate, and its dysfunction results in the
accumulation of cysteine in the basal ganglia. As cys-oxygenase has immunosuppressive and antiapoptotic
properties. As described earlier, inflammatory cytokines teine efficiently binds iron, it was postulated that this
results in tissue damage by promoting oxidative stresshave direct and indirect effects on expression of pro-
teins of iron metabolism. Intriguing as it is, we do not (Zhou et al., 2001). An alternative name for this disorder,
“PKAN” (panthothenate kinase-associated neurode-yet understand the reasons for this complex relationship
between iron and immunity. generation), has been proposed.
Iron deficiency also has deleterious consequencesHFE is structurally related to major histocompatibility
class I molecules, suggesting an evolutionary and/or for the brain, particularly in early life. Iron deficiency
appears to alter the chemistry of neurotransmission,functional link between HFE and the immune system.
As described above, HFE is required for appropriate neuronal networks, and myelination. Effects on dopa-
mine receptor and transporter function have been re-hepcidin expression in response to iron overload and
lipopolysaccharide-induced inflammation. Although the ported (Beard, 2003).
In spite of these multiple links between iron metabo-physiological function of hepcidin as an antimicrobial
lism, neuronal function, and neurodegeneration, we areeffector of the innate immune response warrants further
still far from understanding many basic aspects of ironinvestigation, the structural similarities between hep-
metabolism in the brain. Further convergence betweencidin and the -defensins suggests another intriguing
neurobiology and the study of iron metabolism will con-evolutionary link. These connections and parallels can
tribute critical insights into normal brain function andbe rationalized to some extent by considering that iron
common neuropathologies.is an essential nutrient for invading microbes, and se-
questration of iron is an effective measure against them.
The Challenges AheadUndoubtedly, however, there are other important links
Although proteins required for heme biosynthesis andthat are yet to be discovered and understood.
Fe-S cluster assembly have been identified, we knowIron in the Brain
little about intracellular iron trafficking, particularly toDeposition of excess iron in the brain is commonly ob-
mitochondria. Some of these questions can be ad-served in neurodegenerative disorders. In some diseases
dressed using yeast as a model system. Disease models(e.g., Parkinson’s, Alzheimer’s), it is not clear whether
such as frataxin- or ABC7-deficient mice will contributedefects in cerebral iron homeostasis cause degenera-
to the understanding of Fe-S cluster assembly in mam-tive processes or whether iron accumulates as a conse-
mals and intracellular iron management in general. Thequence of another insult. However, accumulating evi-
identification of other disorders associated with defectsdence implicates aberrant neuronal iron metabolism as
in Fe-S protein assembly may bring forward new playersa pathogenic factor (Halliwell, 2001; Perry et al., 2002).
involved in mammalian mitochondrial iron metabolism.In Friedreich ataxia, the most common hereditary
On a grander scale, the problem is to understandataxia, a functional deficiency of frataxin affects intracel-
systemic iron homeostasis: how tissues communicatelular iron distribution as well as Fe-S cluster biogenesis
information about iron needs and coordinate iron deliv-and results in iron accumulation in mitochondria (see
ery at a distance. The urgent issue is to understandabove). While the molecular pathogenesis is still unclear,
the regulation of intestinal iron absorption in molecularmitochondrial dysfunction may result from iron-cata-
detail, to facilitate the development of new treatmentslyzed formation of reactive oxygen species, leading to
for iron deficiency and overload disorders. Efforts to doprogressive neurodegeneration (Pandolfo, 2002). As dis-
this will likely be facilitated by emerging concepts incussed earlier, aceruloplasminemia leads to defective
systems biology. Large datasets derived from genomiccellular iron export and iron accumulation in several
and proteomic studies may require an integrative, com-organs, including the brain. Increased iron levels and
putational approach to define the complexities of ironconsequent lipid peroxidation correlate with the extent
homeostasis at the level of the whole organism inter-of neurodegeneration in humans and Cp-deficient mice
acting with its environment.(Miyajima et al., 2002). Similarly, a mutation in the car-
Finally, a combination of insights into cellular iron me-boxyl terminus of the ferritin L chain results in a rare
tabolism and systemic iron homeostasis will help to inte-movement disorder, neuroferritinopathy. Spherical in-
grate our understanding of local, organ-specific or cellclusions of ferritin and iron accumulate in the basal gan-
type-specific management of iron. Iron metabolism cer-glia of patients together with ubiquitin and tau (Curtis
tainly is not a rusty topic!et al., 2001).
We apologize to all our colleagues whose work weIn mice, global loss of IRP2 results in abnormal iron
could not cite due to limitations in space.deposition in the CNS, causing abnormal movements
(ataxia, bradykinesia) and tremors. It has been proposed
Referencesthat, in the absence of IRP2, overexpression of H- and
L-ferritin causes axonal degeneration (LaVaute et al., Abboud, S., and Haile, D.J. (2000). A novel mammalian iron-regu-
2001). However, targeted inactivation of one murine lated protein involved in intracellular iron metabolism. J. Biol. Chem.
275, 19906–19912.H-ferritin allele leads to increases in brain markers of
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